Blog

Continue Reading

  • Hagastrand, Autograph Collection, launches spa with Gongmatic experience

    Hagastrand, Autograph Collection, launches spa with Gongmatic experience

    Hagastrand offers a new kind of immersive gong experience called Gongmatic

    Nobis’ wellness expert Alla Sokolova worked on the concept

    Inside a 70sq m acoustically-insulated room, a 60-inch self-playing gong is hand-tuned to resonate on its…

    Continue Reading

  • Breakthrough could offer a new therapeutic option for stopping diabetes-induced complications

    Breakthrough could offer a new therapeutic option for stopping diabetes-induced complications

    Researchers from the University at Albany and NYU Grossman School of Medicine have found a way to block a key cellular pathway known to drive chronic inflammation and impaired wound healing in people with diabetes. 

    The…

    Continue Reading

  • Eli Lilly (LLY) earnings Q3 2025

    Eli Lilly (LLY) earnings Q3 2025

    Lilly Chair and CEO Dave Ricks speaks during a press conference for Eli Lilly and Company in Houston, Texas, U.S., Sept. 23, 2025.

    Antranik Tavitian | Reuters

    Eli Lilly on Thursday reported third-quarter earnings and revenue that topped estimates and hiked its full-year outlook, as the company continued to see strong demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro.

    Shares of the company rose 5% in premarket trading Thursday.

    The pharmaceutical giant now expects its fiscal 2025 revenue to come in between $63 billion and $63.5 billion, up from a previous guidance of $60 to $62 billion. Eli Lilly also expects full-year adjusted profit to come in between $23 and $23.70 per share, up from its previous outlook of $21.75 to $23 a share.

    Eli Lilly said the guidance reflects President Donald Trump’s existing tariffs as of Thursday, but does not include his threatened levies on pharmaceuticals imported into the U.S.

    Mounjaro raked in $6.52 billion in revenue for the quarter, up 109% from the same period a year ago. That blew past the $5.51 billion that analysts were expecting, according to StreetAccount. 

    Zepbound, which entered the market roughly two years ago, posted $3.57 billion in revenue for the third quarter. That’s up 184% from the year-earlier period and slightly ahead of the $3.5 billion that Wall Street was expecting, according to StreetAccount estimates.

    Here’s what Eli Lilly reported for the third quarter compared with what Wall Street was expecting, based on a survey of analysts by LSEG: 

    • Earnings per share: $7.02 adjusted vs. $5.69 expected
    • Revenue: $17.60 billion vs. $16.01 billion expected

    The results come as Eli Lilly works to maintain its edge over chief rival Novo Nordisk in the booming market for a class of obesity and diabetes drugs called GLP-1s.

    The company posted third-quarter revenue of $17.60 billion, up 54% from the same period a year ago. 

    Sales in the U.S. jumped 45% to $11.30 billion. Eli Lilly said that was driven by a 60% increase in volume — or the number of prescriptions or units sold — for its products, primarily for Mounjaro and Zepbound. That was partially offset by lower realized prices of the drugs, the company said.

    The pharmaceutical giant booked net income of $5.58 billion, or $6.21 per share, for the third quarter. That compares with net income of $970.3 million, or $1.07 per share, a year earlier. 

    Excluding one-time items associated with the value of intangible assets and other adjustments, Eli Lilly posted earnings of $7.02 per share for the second quarter.

    The results underscore Eli Lilly’s strong advantage in the booming GLP-1 drug market.

    The company has gained the majority market share over the last year, thanks to the strong profile of its weight loss and diabetes injections and a boost from its direct-to-consumer sales, among other efforts. Eli Lilly took another stride to boost access to Zepbound on Wednesday, partnering with Walmart to offer in-store pickup of discounted vials of the drug for cash-paying patients.

    The company is now betting on its closely-watched experimental obesity pill, orforglipron, to solidify its dominance in the space, especially as Novo Nordisk and other drugmakers race to bring their own pills or next-generation injections to the market. 

    On Thursday, Novo Nordisk launched a rival bid for U.S. obesity biotech company Metsera, hijacking an offer from Pfizer as it races to catch up to Eli Lilly.

    This story is developing. Please check back for updates.

    Continue Reading

  • TRG Pakistan quarterly profit soars 185% on back of foreign associate’s earnings

    TRG Pakistan quarterly profit soars 185% on back of foreign associate’s earnings

    KARACHI: TRG Pakistan Limited has announced an explosive start to its financial year 2026, reporting a profit after taxation of Rs. 6.87 billion for the quarter ended September 30, 2025. This represents a staggering 185% increase compared to the Rs. 2.41 billion profit recorded in the same quarter last year, underscoring the company’s heavy reliance on its strategic international investments.

    The massive surge in profitability is directly attributable to the company’s share of profit from an equity-accounted investee, which skyrocketed to Rs. 8.30 billion for the quarter. This performance dramatically boosted earnings per share (EPS) to Rs. 12.59, up from Rs. 4.41 in the prior year period.

    This windfall has significantly strengthened the company’s balance sheet. Total equity climbed to Rs. 44.45 billion as of September 30, 2025, a substantial increase from Rs. 37.93 billion just three months prior. The growth was primarily fueled by a rise in unappropriated profit. It is important to note that the company recorded an other comprehensive loss of Rs. 356 million due to the translation of its net investment in the foreign associate, a non-cash accounting adjustment reflecting currency movements.

    Despite the blockbuster profitability, TRG Pakistan’s core operating activities remained minimal, reporting an operating loss of Rs 191 million, higher than last years’ Rs 132 million. For investors, the results cement TRG Pakistan’s identity as a holding company whose value is predominantly derived from its stake in a high-performing foreign entity, with quarterly results subject to the performance and currency translation of that investment.

    Following the announcement, the TRG stock price dropped by almost 1% mimicking a larger market trend as the PSX also dropped 1.1% during the day’s trade.


    Continue Reading

  • Fortnite Spice skin price and leaving date for the Meow-o’-Lantern collection

    Fortnite Spice skin price and leaving date for the Meow-o’-Lantern collection

    The Meow-o’-Lantern collection has come to Fortnite bringing the Spice skin in tow, and it’s a surprisingly cheap cosmetic to pick up to celebrate the last of the Fortnitemares event with.

    Continue Reading

  • Iron ore futures close higher-Xinhua

    DALIAN, Oct. 30 (Xinhua) — Iron ore futures closed higher on Thursday in daytime trading at the Dalian Commodity Exchange (DCE).

    The most active iron ore contract for January 2026 delivery gained 3 yuan (about 42 U.S. cents) to close at 802.5 yuan per tonne.

    On Thursday, the total trading volume of 12 listed iron ore futures contracts on the exchange was 409,689 lots, with a turnover of about 32.83 billion yuan.

    As the world’s largest importer of iron ore, China opened the DCE iron ore futures to international investors in May 2018. ■

    Continue Reading